Complete 2017-18 Global Cord Blood Banking Industry Report

  • ID: 4403058
  • Report
  • Region: Global
  • 257 Pages
  • BioInformant
1 of 5

FEATURED COMPANIES

  • AllCells
  • Cell Care (Australia)
  • Cryolife
  • GTCR, LLC
  • MiracleCord
  • PromoCells
  • MORE

The global cord blood banking industry has matured substantially over the past few years, creating both serious threats and novel opportunities.

Serious threats to the industry include:

  • New accreditation requirements that have increased the cost structure of cord blood banks
  • A decline in cord blood transplants, within the U.S. and other geographical regions
  • Low rates of turnover for stored cord blood units
  • Expensive cord blood transplantation procedures, costing from $200-300K each
  • Difficulty with educating obstetricians about cellular therapies
  • Poor press coverage in many regions worldwide, including major news outlets

Other uncontrollable factors that could threaten the industry include: new legislation, changes in transplant reimbursement, continually evolving accreditation requirements, the potential for competitive approaches to be shown as more optimal, patent challenges for processing or transplant technologies, changes in public perception of private vs. public banking, shift in policy recommendations by influential medical organizations, and changes in government support.

Marketing pressures are also impacting the industry, with the term “cord blood” becoming one of the 20 most expensive search terms on Google, reaching more than $20 per click for global search traffic and over $70 per click for U.S. search traffic.

However, there are also emerging opportunities, including:

  • The potential to expand market size through increasing public awareness
  • New clinical trial data supporting applications for hematopoietic stem cells (HSCs) from cord blood and mesenchymal stem cells (MSCs) from cord tissue
  • Improving public perception toward stem cell therapies
  • Substantial deal-making within the industry, including mergers, acquisitions, and funding rounds
  • The potential for cross-organizational collaboration through formation of Cord Blood Industry Associations (occurring in within U.S. and South America)
  • A trend toward diversification within the industry, with cord blood banks effectively becoming stem cell banks through the storage of cord blood, cord tissue, and in some cases, placental tissue, amniotic fluid, and more

Within this rapidly evolving ecosystem, those who choose to commit to understanding current opportunities and threats will be positioned for a substantial strategic advantage.

Key Report Findings

The report is designed to guide the decision-making of cord blood banks worldwide, as well as to advise private, corporate, and institutional investors entering into this market.

The report analyzes the types of investments being made within the cord blood marketplace, including investments made by:

  • ABS Capital Partners & HLM Management
  • KKR & Company
  • Bay City Capital
  • GTCR, LLC
  • Excalibur

Key findings contained within the report include:

  • Market size determinations for the global cord blood market
  • Trend rate data for umbilical cord blood grants, patents, and scientific publications
  • Clinical trial rate analysis, including comparison of cord blood vs. cord tissue frequency
  • Rates of global cord blood storage (units per year)
  • Rates of global cord blood transplant (units per year)
  • Current and future conditions treatable with cord blood
  • Probability of requiring a stem cell transplant by age
  • Trends in medical opinions of cord blood banking
  • Changes in legislative support for cord blood banking
  • Investors impacting the global cord blood banking marketplace
  • Competitive environment analysis, including assessment of cord blood market leaders
  • Influential alliances within the cord blood industry
  • “SWOT” analysis for global cord blood industry (Strengths, Weaknesses, Opportunities, Threats)
  • Crucial trends and unmet market needs
  • And much more
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AllCells
  • Cell Care (Australia)
  • Cryolife
  • GTCR, LLC
  • MiracleCord
  • PromoCells
  • MORE

I.  Abstract

II. Timeline of Key Events

III.   Technical & Medical Characteristics of Cord Blood
A. Introduction to Cord Blood and Cord Tissue
B. Definitions and Nomenclature
C. Technical Advantages of Cord Blood
D. Likelihood of Needing a Stem Cell Transplant
E. Comparison of Cord Blood, Bone Marrow, & Peripheral Blood Stem Cell Transplant
F. Conditions Treatable with Cord Blood Transplant

IV. Cord Blood Market Overview
A. Stem Cell Storage Service Offerings
B. Public vs. Private Cord Blood Storage

V.  Cord Tissue Market Overview
A. History of Cord Tissue Storage
B. Comparison of Cord Blood & Cord Tissue Storage
C. Clinical Trials Investigating Cord Tissue Derived Mesenchymal Stem Cells (CT-MSCs)
D. Sources of Mesenchymal Stem Cells
E. Market Penetration of Cord Tissue Storage within the U.S.
F. Market Penetration of Cord Tissue Storage Worldwide
G. Pricing of Cord Tissue Storage (Global Analysis)

VI. Benefits of Mesenchymal Stem Cells
A. Key Dates in the Discovery of MSCs
B. Physical Assessment of MSCs
C. Benefits of MSCs Relative to Other Stem Cells
1. Well-Characterized
2. Non-Controversial
3. Diverse Differentiation Potential
4. Ease of Growth in Culture
5. Flexible Propagation
6. Clinically Relevant Volumes
7. Role as Regulatory Cells
8. Delivery of Gene Products
9. Favorable Immune Status
10. Commercially Available Research Tools

VII. Cord Blood Industry Accreditations
A. Overview of Cord Blood Industry Accreditation
B. AABB Accreditation

VIII. Key Processing Technologies within the Cord Blood Marketplace
A. AutoXpress® Platform (“AXP®”) and BioArchive System  (By Thermogenesis, a Division of Cesca Therapeutics)
B. Sepax (By Biosafe, in Eysins, Switzerland)
C. PrepaCyte®-CB (By BioE; Cryo-Cell Purchased Rights in U.S.)
D. Cord Blood 2.0TM (By Americord)
E. Other Cord Blood Processing Technologies

IX. Strategic Collaborations: Key Alliances within the Cord Blood Industry
A. Cord Blood Registry and Women’s Health Alliance (Largest Women’s Healthcare Groups)
B. ViaCord and Destination Maternity (Largest Retailer of Maternity Clothing)
C. Precious Cells Miracle and the Croydon Health Services NHS Trust
D. CarePilot and “Cord for Life” (Lifeforce Cryobank’s Cord Blood Storage Program)
E. Cesca Therapeutics and UpState Public Cord Blood Bank
F. New York Blood Center and Pluristem Therapeutics Collaborate on Adjuvant Therapy for Cord Blood Transplantation
X. Pairing Cord Blood Banking with Prenatal / Neonatal / Maternal Health Services
A. Natera, a leader in genetic testing, launches EverCord™ Cord Blood and Tissue Banking Services (March 2017)
B. ViaCord, owned by PerkinElmer, Launched Newborn Genetic Screening (August 2017)
C. Human Longevity Inc. Acquired LifeBankUSA (owned by Celgene); LifeBankUSA Passed to Celularity, Inc.
D. AMAG Pharmaceuticals acquired Cord Blood Registry to Bolster Maternal Health Products (June 2015)
E. Donor Egg Bank Offers Free Processing of Client’s Newborn Cord Blood through FamilyCord

XI. Cord Blood Industry Consolidation (Mergers and Acquisitions)
A. Global Analysis of Mergers & Acquisitions
B. Role of Holding Companies within the Global Cord Blood Industry

XII. Technologies for Cord Blood Stem Cell Expansion
A. Key Strategies for Cord Blood Expansion
1. NiCord
2. Notch-1 Ligand
3. StemRegenin-1 (SR1)
4. UM171
5. Enforced Fucosylation
6. Dimethyl Prostaglandin E2 (PGE2)
B. Case Study: Gamida Cell Ltd, Industry Leader in Cord Blood Expansion Technology

XIII.  Diversification of Stem Cell Storage Services
A. Dental Stem Cell Storage
1. Overview of Dental Stem Cell Storage
2. Leading Dental Stem Cell Companies
3. Timeline of Events for Dental Stem Cell Companies
4. Key Competitors for Dental Stem Cell Storage
5. BioEden, Leading Provider of Dental Stem Cell Storage Worldwide
B. Adipose-Derived Stem Cell Storage
C. Other Types of Stem Cell Storage

XIV. Comparison of U.S. Cord Blood Market Leaders
A. Cord Blood Registry
B. ViaCord
C. Cryo-Cell International
D. Comparison of Top 3 Private U.S. Cord Blood Banks

XV. Comparison of Global Cord Blood Market Leaders
A. Cryo-Save Group (an Esperite N.V Company)
B. China Cord Blood Corporation (Owned by Sanpower Group)
C. LifeCell International
D. Comparison of International Cord Blood Banks

XVI. SWOT Analysis for Cord Blood Industry
A. Strengths
B. Weaknesses
C. Opportunities
D. Threats

XVII. Regulation of the Cord Blood Marketplace
A. Regulation of HCT/Ps by the U.S. FDA
B. 21st Century Cures Act and REGROW Act
C. Accelerated Approval Pathways for Cell Therapies in Japan
D. Accelerated Approval Regulator Pathways Worldwide

XVIII.  Trend Rate Analysis
A. Scientific Publication Rate Analysis
B. Grant Funding Analysis
C. Patent Analysis
D. Clinical Trial Analysis
E. Market Penetration Rate of Cord Blood Storage

XIX. Cord Blood Online Marketing Analysis
A. Cost to Win Online Traffic for the Term “Cord Blood” in Google AdWords
B. Cost to Win Online Traffic for the Term “Cord Tissue” in Google AdWords

XX. Key Cord Blood Industry Benchmarks
A. Medical Society Opinions of Cord Blood Banking
B. Rates of Parental Awareness
C. Rates of Worldwide Storage, by Year
D. Transplant Data
E. Impact of Haploidentical Transplant

XXI. Quality Guarantee Comparison

XXII.  Market Size Analysis
A. Definitions
B. Methodology
1.  Roll-up All Competitor Sales (“Gold Standard”)
2.  Weighted Analysis of Industry Leaders (“Silver Standard”)
3.  Survey Customers for How Much They Spend in the Market (“Bronze Standard”)
C. Types of Market Participants
1. Largest Market Participants
2. Mid-Sized Market Participants
3. Small Sized Participants
4. Public Cord Blood Banking Sector
5. Summary of Findings
D. Market Size Determination for Cord Blood and Tissue Banking Market
E. Market Segmentation for All Applications of Cord Blood and Cord Tissue
1. Biobanking
2. Use in Hematopoietic Stem Cell Transplantation (HSCT)
3. Cellular Therapies
4. Genetic Manipulation
5. Research Tools
F. Market Size Determinations by Market Segment

XXIII. Cord Blood Industry Leadership
B. Top Ten Most Influential Cord Blood Banks Worldwide
1. Cord Blood Registry
2. ViaCord
3. Cryo-Cell International
4. China Cord Blood Corporation (CCBC)
5. Cryo-Save
6. Cryoholdco
7. LifeCell International
8. Vita34 AG
9. Crioestaminal
10. National Cord Blood Program (NCBP) at the New York Blood Center

XXIV. Global Cord Blood Conferences and Events

XXV. Investors and Acquisitions Impacting the Global Cord Blood Industry
A. Investors Impacting the Global Cord Blood Market
B. Similarities between Acquisition of Cord Blood Registry & ViaCord

XXV. Geographic Analysis of Evolving Cord Blood Industry Conditions
A. China
B. France and Italy
C. Taiwan
D. Ecuador
E. South Africa
F. Brazil

XXVI. Summary of Conclusions

APPENDIX A - Conditions Treatable with Hematopoietic Stem Cell Transplant (Including Cord Blood Stem Cell Transplant)
APPENDIX B - AABB Accredited Cord Blood Banks Worldwide
APPENDIX C - List of U.S. Cord Blood Banks by Type of Bank (Private, Hybrid, or Public)
APPENDIX D - Global List of Cord Blood Banks Worldwide

List of Tables/Figures
Figure 1. Cord Blood Market Segmentation
Figure 2.  Sources of Mesenchymal Stem Cells (MSCs)
Figure 3. Benefits of MSCs Relative to Other Stem Cells
Figure 4. Circle Visualization of “Cord Blood” Clinical Trials (RePORTER Tool)
Figure 5. Common Cryo-Cell Landing Page
Figure 6. Common ViaCord Landing Pages
Figure 7. Comparison of Umbilical Cord Blood vs. Umbilical Cord Tissue
Figure 8. Cord blood treatment options
Figure 9. Cost to Win Online Traffic for Term “Cord Blood” in Google AdWords on a Global Basis
Figure 10. Cost to Win Online Traffic for Term “Cord Blood” in Google AdWords within the U.S.
Figure 11. Density of Research Grants in the U.S. Containing “Cord Blood” in Description
Figure 12. Key Processing Technologies within the Cord Blood Banking Marketplace
Figure 13. Gamida Cell’s Clinical Pipeline Involving Its Cord Blood Derived Products
Figure 14. Geographical Breakdown of “Cord Blood” Clinical Trials Registered at ClinicalTrials.gov
Figure 15. Ground-breaking Years in Transplant History
Figure 16. Key Dates in the Discovery of Mesenchymal Stem Cells
Figure 17. Leading Landing Page Used by CBR
Figure 18. Map of Current Mesenchymal Stem Cell (MSC) Clinical Trials on ClinicalTrials.gov
Figure 19. Search Terms Containing the Phrase “Cord Blood” Within Them (Geography: USA Only)
Figure 20. Search Terms Containing the Phrase “Cord Blood” Within Them (Geography: Worldwide)
Figure 21. Sites of Organizations that Have Received Cord Blood Grants
Figure 22. Technical Advantages of Cord Blood over Bone Marrow or Peripheral Blood
Figure 23. Leading Assignees for Cord Blood Patents
Figure 24. Potential Strategies for Cord Blood Expansion
Graph 1. Likelihood of Requiring a Stem Cell Transplant (From Cord Blood, Bone Marrow, or Peripheral Blood)
Graph 2. # of "Cord Blood" Patents by Country (Title and Abstract Search)
Graph 3. # of Grants Funding Projects with "Cord Blood" in Description (RePORTER Tool)
Graph 4. Breakdown of Global Cord Blood and Tissue Market by Type of Participant
Graph 5. Countries with AABB Accredited Cord Blood Facilities
Graph 6. Market Contributions by Type of Market Participants
Graph 7. Market Contributions by Type of Market Segment
Graph 8. Number of Clinical Trials with "Cord Blood" in the Description
Graph 9. Number of Cord Blood Units in the BMDW Cord Blood Registry, by Year
Graph 10. Percentage of Cord Blood Banks Worldwide Offering Cord Tissue Storage Services
Graph 11. Percentage of Global Market for Cord Blood and Cord Tissue Banking
Graph 12. Registry Transplants by Cell Source
Graph 13. Types of Transplants Used by the 70,000 Patients Requiring Hematopoietic Stem Cell Transplantation Each Year
Graph 14. Year-Over-Year Comparison of Stem Cell Scientific Publications, by Stem Cell Type
Table 1.  U.S. Cord Blood Banks Offering Cord Tissue Storage in 2013 (Historical Snapshot 1)
Table 2.  U.S. Cord Blood Banks Offering Cord Tissue Storage in 2015 (Historical Snapshot 2)
Table 3. Adulthood Probability of Requiring a Stem Cell Transplant
Table 4. Breakdown of Global Market by Type of Participant
Table 5. Childhood Probability of Requiring a Stem Cell Transplant
Table 6. Clinical Trials Investigating the Use of Cord Tissue Derived Mesenchymal Stem Cells (CT-MSCs)
Table 7. Clinical Trials Underway Involving Use of Wharton’s Jelly, a Rich Source of Cord Tissue MSCs
Table 8. Companies Offering Adipose-Derived Stem Cell Storage (Both Cord Blood Banks and Specialty Companies)
Table 9. Companies Offering Dental Stem Cell Storage, Including Cord Blood Banks and Specialty Companies
Table 20. Comparative Analysis of Pricing Among Leading U.S. Private Cord Blood Banks
Table 21. Comparison of Acquisition of Cord Blood Registry by AMAG Pharmaceuticals and ViaCord by PerkinElmer
Table 22. Comparison of Quality Guarantees Among Private U.S. Cord Blood Banks (Ranked by Value of the Guarantee)
Table 23. Comparison of Services and Features Among Leading Private Cord Blood Banks Worldwide
Table 24. Comparison of Services and Features Among Leading U.S. Private Cord Blood Banks
Table 25. Comparison of Stem Cell Publication Rates by Stem Cell Type
Table 26. Cord Blood Banking Opinions Issued by Medical Societies
Table 27. Cord Blood Clinical Trials Registered at ClinicalTrials.gov
Table 28. Cord Blood Units in the Bone Marrow Donors Worldwide Database
Table 29. Countries Containing AABB Accredited Cord Blood Banks
Table 30. Disease Categories That May Be Treatable with HSCT in the Future
Table 31. Disease Categories Treatable with Hematopoietic Stem Cell Transplantation (HSCT)
Table 32. Esperite N.V. Subsidiaries Operating Worldwide
Table 33. Free Cord Blood Programs for Families in Need in the U.S.
Table 34. Geographic Breakdown of “Cord Blood” Clinical Trials Registered at ClinicalTrials.gov
Table 35. Global Cord Blood Conference and Events
Table 36. Global Private Cord Blood and Tissue Banking Market, by Type of Market Participant
Table 37. Google AdWords Pay-Per-Click Prices for Cord Blood Related Search Terms
Table 38. Industry Investors within the Cord Blood Market
Table 39. Major Acquisitions within the Global Cord Blood Market
Table 40. Market Contribution in USD ($) by Market Segment
Table 41. Market Contribution in USD ($) by Type of Market Participant
Table 42. Market Size Determinations by Market Segment
Table 43. Number of Cord Blood and Tissue Units Stored by Mid-Sized Private Cord Blood Banks
Table 44. Number of Cord Blood and Tissue Units Stored in Largest Private Cord Blood Banks
Table 45. Opportunities within the Global Cord Blood Banking Market
Table 46. Patents Containing “Cord Blood” in the Title or Abstract (Google Patent Search)
Table 47. Percent of Cord Blood Banks Worldwide Offering Cord Tissue Storage Services
Table 48. Percent of Total Global Market by Type of Cord Blood Bank
Table 49. Pricing Structures for Umbilical Cord Tissue
Table 50. Strengths of the Global Cord Blood Banking Market
Table 51. Threats to the Global Cord Blood Banking Market
Table 52. Timeline of Key Events within the Cord Blood Industry
Table 53. Transplants by Cell Source
Table 54. Trend Rate Analysis of Cord Blood and Cord Tissue Scientific Publications
Table 55. Trend Rate Analysis of Cord Blood Grants (RePORTER Tool)
Table 56. Trends in Cord Blood Industry Growth by Geography and Sector
Table 57. Types of Stem Cell Banking
Table 58 Unique Differentiators for CBR, ViaCord, and Cryo-Cell
Table 59. Weaknesses of the Global Cord Blood Banking Market
Table 60: Fetal Sources for Mesenchymal Stem Cell (MSC) Isolation
Table 61: Adult Sources for Mesenchymal Stem Cell (MSC) Isolation
Table 62: Cord Blood Banks Securing Cord Blood Patents as the Assignee

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • AllCells
  • Cell Care (Australia)
  • Cryolife
  • GTCR, LLC
  • MiracleCord
  • PromoCells
  • MORE

A Global Market Requires Global Understanding

While these factors vary somewhat by market, there is a substantial advantage to having a global understanding of the market. You need to understand successes and failures by region to be fully informed of your competitive environment. You need to have a firm understanding of emerging trends that could expand to new regions and impact your business model. In addition, research advances, clinical trial findings, and technology advances do not know international boundaries. They are shared nearly instantly from region-to-region.

The cord blood market is global in nature and understanding dynamics limited to your region is not sufficient for making strategic, informed, and profitable decisions.

Furthermore, cord blood banks now exist in every developed country, as well as within most developing nations. With approximately 500 cord blood banks operating worldwide, maturation of the global cord blood market means that each cord blood bank is now fighting harder for market share.

Currently, the U.S. cord blood banking industry is the most mature cord blood banking market in the world, having the:

  • First company to offer cord blood storage (1995)
  • Largest total number of industry participants (both public and private)
  • Greatest number of cord blood units (CBU) stored
  • Most cord blood units banked relative to population

However, other regions have contributed major events as well.

For instance, a Taiwanese company, HealthBanks Biotech Company Ltd. became the first company to offer cord tissue storage in 2008. It was not until July 2010 that the first private U.S. cord blood bank began offering the service (Cord Blood Registry). Since then, the trend of cord tissue storage has had a significant impact on the cord blood banking industry, with a large percentage of cord blood banks worldwide offering the service.

In China, the government shocked the cord blood industry worldwide when it announced that only one cord blood bank would be allowed to operate within each province, and official government support, authorization, and permits would be required.

While the China Cord Blood Corporation has since earned permits for three of the seven Chinese provinces (holding majority share of the Chinese cord blood market) and is now competing as one of the fastest growing cord blood banks in the world, several other providers of cord blood services disappeared when this legislation was passed.

In Italy and France, it is illegal to privately store one’s cord blood, which has fully eliminated the potential for a private market to exist within the region.

In Ecuador, the government is now creating the first public cord blood bank and has instituted laws such that private cord blood banks cannot approach women about private cord blood banking options during the first six months of pregnancy. This has created a crisis for the private banks, and there are now only two remaining in Ecuador.

Clearly, it is vital to understand the market dynamics and risks, as well as the emerging opportunities within different regions of the world.

Cord Blood Stem Cells, as Compared to Other Stem Cell Types

Since the first stem cell transplant occurred more than 50 years ago (1957), there has been a nearly exponential increase in stem cell transplants, and in late 2012, the millionth stem cell transplant occurred, a landmark event in stem cell medicine.

While bone marrow stem cells are the most commonly recognized type of stem cell used for transplantation, cord blood stem cells are increasingly showing advantages over other stem cell sources, including reduced immune reactions (such as GvHD) and a greater flexibility for HLA-mismatched cord blood units to be used in transplant.

Today, it is clear that the stem cells contained within cord blood banking have the potential to improve and save lives. Since the first cord blood transplant was performed in 1988, stem cells derived from umbilical blood have been used in more than 30,000 transplants worldwide.

Awareness Levels Remain a Substantial Limitation to Cord Blood Market Potential

A study published in the 2006 Journal of Reproductive Medicine showed that a third of expectant parents are unaware of the option to preserve cord blood. Of the two-thirds who have some knowledge, 74% describe themselves as “minimally informed.” The study also identified that 84% of prenatal patients expected their obstetricians to be able to provide them with information on the subject of cord blood banking; however, only about 14% were educated about cord blood banking by their nurse or obstetrician.

Unfortunately, a January 2014 Parent Survey conducted (600+ responses from recent and expectant parents), identified that these percentages have shifted very little since 2006, despite attempts in most countries worldwide to encourage healthcare providers to offer prenatal patients balanced information on public and private cord blood banking options.

Note: Product cover images may vary from those shown
5 of 5
  • ABS Capital Partners & HLM Management
  • AllCells
  • AMAG Pharmaceuticals
  • AlphaCord
  • Americord
  • Bay City Capital
  • BioEden
  • Biocell Center
  • Biosafe
  • CariCord
  • Cell Care (Australia)
  • Cesca Therapeutics
  • China Cord Blood Corporation (CCBC)
  • CorCell
  • Cord Blood Registry (CBR)
  • Cordlife
  • Core23 BioBank
  • Crioestaminal
  • Cryo-Cell International
  • Cryoholdco
  • Cryolife
  • CryoSave
  • Excalibur
  • FamilyCord
  • Fate Therapeutics
  • Future Health Biobank
  • Gamida Cell Ltd.
  • GeneCell International
  • Genesis Bank
  • GTCR, LLC
  • HealthBaby
  • HealthBanks Biotech Company Ltd
  • Human Longevity Inc.
  • Insception Lifebank
  • KKR & Company
  • LifebankUSA
  • LifeCell International
  • Lonza
  • MAZE
  • MiracleCord
  • Nanjing Cenbest
  • Natera, Inc. (EverCordTM)
  • New England Cord Blood Bank
  • National Cord Blood Program (NCBP) at the New York Blood Center
  • Nohla Therapeutics
  • Novartis
  • PacifiCord
  • PerkinElmer
  • Pluristem Therapeutics
  • Precious Cells Group
  • PromoCells
  • ReeLabs
  • Sanpower Group
  • Shandong Cord Blood Bank
  • Stem Cell Cryobank
  • STEMCELL Technologies
  • StemCyte
  • Thermo Fisher Scientific
  • Transcell Biologics Pvt Ltd,
  • VAULT SC Inc.
  • ViaCord
  • Vita34 AG
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll